Pikes Peak Reflux and Weight Loss Surgery

03/20/2026

The science of the "GLP"s.... fascinating!

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are two incretins that bind to their respective receptors and activate...

02/26/2026

No surprise to us...

Both treatment options were found to be effective in a new meta-analysis of nearly 20,000 patients. Surgery, however, had the most substantial long-term impact.

12/16/2025

This...

Evidence from a new Lancet Series suggests diets high in ultra-processed foods ( ) are linked to:
🔹Overeating and higher energy intake,
🔹poor nutritional quality (too much sugar, salt and unhealthy fats; and too little fibre, protein, and certain micronutrients)
🔹and higher exposure to contaminants and potentially harmful additives.

Specific UPF policies can complement existing legislation and improve diets, say authors.

Learn how policies can target UPFs while improving access to healthy alternatives, via the link in comments 💬

12/06/2025

Set Point Theory

Even when we diet and exercise, our bodies can adapt to try to keep us from losing weight, which can lead to weight loss plateaus and regaining lost weight. An obesity specialist explains set point theory, and shares tips on resetting it.

07/02/2025

https://www.soard.org/article/S1550-7289(25)00188-1/fulltext

This...

Avery Brown NYU Langone Health; Suhani Patel NYU Langone Health; Alexander Eduardo Hien Vu NYU Langone Health; Eduardo Somoza NYC Health + Hospitals; Tony Mei NYU Langone; Megan Jenkins NYU Langone; Loic Tchokouani NYU Langone; Marina Kurian NYU Langone; Babak Orandi NYU Langone; Tatiana Figueredo-D...

02/03/2025

This Medical News article discusses how the popularity of the antiobesity drugs semaglutide and tirzepatide may affect uptake of bariatric surgery.

02/03/2025

Great article recently from American Medical Association.
"only about 1% of those eligible to undergo surgical treatment for obesity receive it"

"Bariatric surgery has been shown to be the most effective and longest-lasting treatment for severe obesity.

According to a study presented at the ASMBS’ annual scientific meeting last year, surgery provides more significant, sustained weight loss than GLP-1 drugs. In the systematic review of 4 years of clinical data from thousands of patients, researchers found that bariatric procedures demonstrated an average total weight loss of about 30% a year after the surgery. Up to a decade later, patients weighed a quarter less on average than they did before their operation. Following about 18 months of weekly injections of the GLP-1 drug semaglutide, patients peaked at nearly 15% weight loss while those receiving tirzepatide plateaued at about 22%. Kashyap noted those benefits were achieved with the highest doses and that once treatment stopped, half the lost weight returned within a year.

“Obesity is a chronic disease, so weight regain is definitely plausible with both, but there’s greater relapse with pharmacological therapy than with surgery,” she said."

This Medical News article discusses how the popularity of the antiobesity drugs semaglutide and tirzepatide may affect uptake of bariatric surgery.

01/25/2025

https://www.thelancet.com/pdfs/journals/landia/PIIS2213-8587(24)00316-4.pdf

Current BMI-based measures of obesity can both underestimate and overestimate adiposity and provide inadequate information about health at the individual level, which undermines medically-sound approaches to health care and policy. This Commission sought to define clinical obesity as a condition of....

10/14/2024

Docimo, S., Shah, J., Warren, G. et al. A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?. Surg Endosc (2024).

Background With the prevalence of obesity rising in the US, medical management is of increasing importance. Two popular options for the treatment of obesity are bariatric surgery (e.g. sleeve gastrectomy and Roux-en-Y gastric bypass) and the increasingly popular GLP-1 Receptor Agonists (GLP-1 s). Th...

07/05/2024

The high cost and the tax on the healthcare system remains to be an issue with these injectable weight loss medications. Call us at 719-377-3477 to explore options!

Discover how GLP-1s, a popular class of medications for diabetes and weight loss, are causing health plans to rethink coverage due to high costs.

06/22/2024

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594956/

Metabolic dysfunction-associated steatotic liver disease (MASLD; previously known as nonalcoholic fatty liver liver disease [NAFLD is a growing public health concern globally, affecting not only liver health, but also cardiovascular mortality, and is quickly becoming the leading indication for liver transplantation. By 2030, approximately 30 million Americans will have MASH and
approximately 5% will develop cirrhosis.

We have recently had the opportunity to obtain a FIBROSCAN which is a special ultrasound technology that measures liver stiffness (hardness) and fatty changes in your liver

Call our office at 719-377-3477 for details!

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

05/22/2024

We are doing A LOT of these medications! Give our office a call at 719-377-3477 to schedule a consult!

Despite the recent enthusiasm surrounding GLP-1 receptor agonists (RA) medications for weight loss, bariatric surgery remains the most effective obesity treatment, often leading to greater weight loss and type 2 diabetes remission compared to nonsurgical interventions.1 Patients undergoing bariatric...